Literature DB >> 10690905

Molecular basis off hurthle cell papillary thyroid carcinoma.

C C Cheung1, S Ezzat, L Ramyar, J L Freeman, S L Asa.   

Abstract

Among thyroid neoplasms, Hurthle cell tumors (HCTs) have traditionally been a distinct diagnostic category. Hurthle cell adenomas are encapsulated follicular lesions with benign behavior. Hurthle cell carcinomas exhibit unequivocal capsular and/or vascular invasion; they are aggressive tumors with a poor prognosis. Recently, Hurthle cell papillary thyroid carcinomas (PTCs) have been identified on morphological grounds. We hypothesize that a subset of HCTs represent PTC with clinical, histological, and immunohistochemical features based on specific molecular events. ret/PTC gene rearrangements give rise to novel oncogenes that are unique to PTC. We studied a group (n = 50) of HCTs for ret/PTC gene rearrangements. Tumors were examined for papillary differentiation by light microscopic evaluation of nuclear features, by RT-PCR for ret/PTC gene rearrangements, and by immunohistochemistry for ret. Among 24 noninvasive tumors, 13 contained ribonucleic acid for ret/PTC-1, -2, or -3, and 9 of these were immunoreactive for ret. Among 19 Hurthle cell carcinomas, 15 had focal nuclear hypochromasia with grooves and/or inclusions; expressed transcripts of ret/PTC-1, -2, or-3; and exhibited ret positivity. Tumors with ret/PTC gene rearrangements tended to have lymph node metastases rather than hematogenous spread. Our results indicate that a subset of HCTs exhibit features of PTC that are attributable to specific gene rearrangements, resulting in expression of ret/PTC oncogenes. These data support subclassification of HCTs into three groups: Hurthle cell adenomas, Hurthle cell carcinomas, and Hurthle cell PTC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10690905     DOI: 10.1210/jcem.85.2.6404

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  31 in total

1.  PVALB, a new Hürthle adenoma diagnostic marker identified through gene expression.

Authors:  Janete M Cerutti; Gisele Oler; Rosana Delcelo; Rene Gerardt; Pedro Michaluart; Sandro J de Souza; Pedro A F Galante; Peng Huang; Gregory J Riggins
Journal:  J Clin Endocrinol Metab       Date:  2010-10-06       Impact factor: 5.958

Review 2.  Molecular rearrangements and morphology in thyroid cancer.

Authors:  Todd G Kroll
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

Review 3.  The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid.

Authors:  Sylvia L Asa
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 4.  Diagnostic criteria in well-differentiated thyroid carcinomas.

Authors:  Elsa Fonseca; Paula Soares; Manuel Cardoso-Oliveira; Manuel Sobrinho-Simões
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

Review 5.  Mitochondria and cancer.

Authors:  Valdemar Máximo; Jorge Lima; Paula Soares; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2009-04-03       Impact factor: 4.064

Review 6.  Molecular pathology of well-differentiated thyroid carcinomas.

Authors:  Manuel Sobrinho-Simões; Ana Preto; Ana Sofia Rocha; Patrícia Castro; Valdemar Máximo; Elsa Fonseca; Paula Soares
Journal:  Virchows Arch       Date:  2005-09-28       Impact factor: 4.064

Review 7.  Hurthle Cell Lesion: Controversies, Challenges, and Debates.

Authors:  Michael Shawky; Mahmoud Sakr
Journal:  Indian J Surg       Date:  2015-10-30       Impact factor: 0.656

8.  CBX7 Expression in Oncocytic Thyroid Neoplastic Lesions (Hürthle Cell Adenomas and Carcinomas).

Authors:  Mario Monaco; Gennaro Chiappetta; Concetta Aiello; Antonella Federico; Romina Sepe; Daniela Russo; Alfredo Fusco; Pierlorenzo Pallante
Journal:  Eur Thyroid J       Date:  2014-10-15

Review 9.  [Indication and performance of endocrine surgery. The significance of molecular genetic examination].

Authors:  P E Goretzki; D Wirowski; K Schwarz; P Pohl; H Böhner; A Starke; B J Lammers
Journal:  Chirurg       Date:  2009-02       Impact factor: 0.955

10.  Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.

Authors:  Petra B Musholt; Thomas J Musholt; Saskia C Morgenstern; Karl Worm; Sien-Yi Sheu; Kurt W Schmid
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.